Sumedha Agashe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumedha Agashe has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Vindigni
Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, USA
3 shared publications - Alice Meroni
Department of Gynecology, University of Zurich and University Hospital of Zurich, Schlieren, Switzerland
2 shared publications Amber Carter
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
1 shared publicationAnja Waizenegger
IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy
1 shared publication- Annabel Quinet
Saint Louis University School of Medicine, St. Louis, MO, United States
1 shared publication Barbara Soares
Division of Hematology, Department of Medicine, Washington University in St. Louis, St. Louis, USA
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity
Somatic mutations in the de novo methyltransferase DNMT3A and cytosine demethylase TET2 are common in age-related clonal hematopoiesis and hematopoietic neoplasms. TET2 mutations, unlike DNMT3A mutations, increase sensitivity to PARP inhibitors (PARPi). We find that TET2 loss, but not DNMT3A loss, alters DNA replication fork progression upon treatment with PARPi Olaparib, resulting in longer DNA replication tracts and increased DNA breaks. This reveals a new link between abnormal fork elongation and PARPi sensitivity in TET2-deficient cells. The elongated forks of TET2-deficient cells contain PRIMPOL-dependent single-stranded (ss)-DNA gaps. This phenotype is dependent on the catalytic activity of TET2 and is mitigated by TET1/3 depletion. Furthermore, TET2 loss causes an imbalance in cytosine methylation and an increase in 5hmU modifications. These modifications are processed by SMUG1, creating abasic sites, detectable via a modified DNA fiber method. A CRISPR screen identified the base excision repair nuclease APE1 as linked to increased PARPi sensitivity in TET2-deficient cells. We propose that abasic sites, skipped by PRIMPOL repriming, lead to ssDNA gaps that are converted into DNA breaks by APE1, increasing PARPi toxicity. Finally, we identify TET2 mutations as an unrecognized predictor of PARPi response in bone marrow samples from patients with myeloid malignancies.
- 12 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity
Somatic mutations in the de novo methyltransferase DNMT3A and cytosine demethylase TET2 are common in age-related clonal hematopoiesis and hematopoietic neoplasms. TET2 mutations, unlike DNMT3A mutations, increase sensitivity to PARP inhibitors (PARPi). We find that TET2 loss, but not DNMT3A loss, alters DNA replication fork progression upon treatment with PARPi Olaparib, resulting in longer DNA replication tracts and increased DNA breaks. This reveals a new link between abnormal fork elongation and PARPi sensitivity in TET2-deficient cells. The elongated forks of TET2-deficient cells contain PRIMPOL-dependent single-stranded (ss)-DNA gaps. This phenotype is dependent on the catalytic activity of TET2 and is mitigated by TET1/3 depletion. Furthermore, TET2 loss causes an imbalance in cytosine methylation and an increase in 5hmU modifications. These modifications are processed by SMUG1, creating abasic sites, detectable via a modified DNA fiber method. A CRISPR screen identified the base excision repair nuclease APE1 as linked to increased PARPi sensitivity in TET2-deficient cells. We propose that abasic sites, skipped by PRIMPOL repriming, lead to ssDNA gaps that are converted into DNA breaks by APE1, increasing PARPi toxicity. Finally, we identify TET2 mutations as an unrecognized predictor of PARPi response in bone marrow samples from patients with myeloid malignancies.
- Open Access
- 6 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2506-2520
Synthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated–Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.
- 6 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2506-2520
Open AccessSynthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated–Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.
- Open Access
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq0648
NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors
DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8–Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq0648
Open AccessNEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors
DNA topoisomerase 1 (TOP1) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8–Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.
- Open Access
- 8 April 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Smc5/6 functions with Sgs1-Top3-Rmi1 to complete chromosome replication at natural pause sites
Smc5/6 is essential for genome structural integrity by yet unknown mechanisms. Here we find that Smc5/6 co-localizes with the DNA crossed-strand processing complex Sgs1-Top3-Rmi1 (STR) at genomic regions known as natural pausing sites (NPSs) where it facilitates Top3 retention. Individual depletions of STR subunits and Smc5/6 cause similar accumulation of joint molecules (JMs) composed of reversed forks, double Holliday Junctions and hemicatenanes, indicative of Smc5/6 regulating Sgs1 and Top3 DNA processing activities. We isolate an intra-allelic suppressor of smc6-56 proficient in Top3 retention but affected in pathways that act complementarily with Sgs1 and Top3 to resolve JMs arising at replication termination. Upon replication stress, the smc6-56 suppressor requires STR and Mus81-Mms4 functions for recovery, but not Srs2 and Mph1 helicases that prevent maturation of recombination intermediates. Thus, Smc5/6 functions jointly with Top3 and STR to mediate replication completion and influences the function of other DNA crossed-strand processing enzymes at NPSs.
- 8 April 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessSmc5/6 functions with Sgs1-Top3-Rmi1 to complete chromosome replication at natural pause sites
Smc5/6 is essential for genome structural integrity by yet unknown mechanisms. Here we find that Smc5/6 co-localizes with the DNA crossed-strand processing complex Sgs1-Top3-Rmi1 (STR) at genomic regions known as natural pausing sites (NPSs) where it facilitates Top3 retention. Individual depletions of STR subunits and Smc5/6 cause similar accumulation of joint molecules (JMs) composed of reversed forks, double Holliday Junctions and hemicatenanes, indicative of Smc5/6 regulating Sgs1 and Top3 DNA processing activities. We isolate an intra-allelic suppressor of smc6-56 proficient in Top3 retention but affected in pathways that act complementarily with Sgs1 and Top3 to resolve JMs arising at replication termination. Upon replication stress, the smc6-56 suppressor requires STR and Mus81-Mms4 functions for recovery, but not Srs2 and Mph1 helicases that prevent maturation of recombination intermediates. Thus, Smc5/6 functions jointly with Top3 and STR to mediate replication completion and influences the function of other DNA crossed-strand processing enzymes at NPSs.